As a pioneer in the field, Mayo Clinic plays an integral role by developing new tests to help align patients with new therapies for plasma cell disorders. Our algorithmic approach ensures that the right tests are ordered at the right time and that healthcare providers get clinically actionable answers for their patients faster. And testing with Mayo Clinic means 24/7 access to our physician and laboratory experts, who are leaders in their fields.
Breaking down the facts
When a patient presents with a monoclonal protein (M-protein) disorder, the answer is not always multiple myeloma. From the more common diagnosis of monoclonal gammopathy of undetermined significance (MGUS) to rarer findings such as amyloid light-chain (AL) amyloidosis or POEMS syndrome, it is becoming more recognized that plasma cell neoplasms are not just one disease, and they are characterized by marked protein, cytogenetic, molecular, and proliferative heterogeneity.
Clinicians are increasingly challenged to provide answers in this rapidly changing environment. Advances in testing methodologies, novel therapies, and individualized treatment regimens continually add to the complexity of helping patients. Whether you’re screening, diagnosing, or monitoring patients, we offer leading-edge testing that helps you provide the best care for your patients, locally.
No posts available.
Fill out the form below and one of our specialists will be in touch.